Blocking the jab

Maduro and Guaidó struggle to bring vaccines to Venezuela.

Remarkably, members of the government of disputed President Nicolás Maduro and advisers to the National Assembly, chaired by Presidential challenger Juan Guaidó, have been working together under an agreement to acquire medical equipment and, more recently, design a vaccine purchase and rollout plan.

The director of human rights at a prestigious Venezuelan university reported, “The team had secured an agreement for 2.5 million AstraZeneca vaccines through the COVAX mechanism. Guaidó was to provide funding while Maduro would allow the government structure under his control to distribute the vaccines.”

“Guaidó was to provide funding while Maduro would allow the government structure under his control to distribute the vaccines.”

Director of human rights, university, Venezuela

Unfortunately, President Nicolás Maduro decided to halt the import of AstraZeneca vaccines after it was subject to review by European health authorities following allegations of potential links to blood clot risks.

While this may have been a legitimate concern, apparently the Maduro administration was also angered that the agreement between them and the National Assembly was made public. As the founder of a Venezuelan NGO explained, “The Maduro administration saw the leak of the agreement to the media as a breach of the terms of the agreement and an attempt by the National Assembly and Juan Guaidó to score political points.”

During the first half of April, Venezuela imported 750,000 vaccine doses, which would cover less than 1.3% of the population. The country needs 20 million vaccines to cover 70% of the population, including one million health workers.

A senior medical official told us, “So far, the Venezuelan authorities have only authorised the administration of the Russian Sputnik V vaccine and the vaccine manufactured by the Chinese company Sinopharm. However, only small batches have been administered, mainly to senior officials of the Maduro Administration and to the health personnel of public entities.”

“Only small batches have been administered, mainly to senior officials of the Maduro Administration and to the health personnel of public entities.”

Senior medical official, Venezuela

Furthermore, there have been reports that Maduro’s party, the Partido Socialista Unido de Venezuela, have been refusing to administer the vaccine to anyone without a Carnet de la Patria. A political official explained, “The ‘Carnet de la Patria’ is an ID card established by the Maduro Administration whose declared objective is the distribution of social benefits and subsidies. In truth, it is a sophisticated mechanism that collects very detailed information on the population and enables Maduro to reward people who vote for him. The middle-class that oppose the Maduro Administration have mostly refused to register for the Carnet because they identify it as a mechanism of social control and identification with Chavismo.”

The government is facing mounting pressure both at national and international level. In Caracas, the Citizens Platform for the Defence of the Constitution (PCDC) and Critical Thinking Group (GPC) have requested more transparency from the government in vaccination programme funds allocations. The Pan America Health Organisation said that Maduro had paid USD 200 million to Russia for ten million vaccines of which the country has only received 300,000. A spokesperson for the organisation criticised the government’s lack of planning but also emphasised the problems that the country faces in importing medical equipment due to US sanctions.

If this wasn’t bad enough, a black-market for vaccines has been established by the desperate population. The black market is divided into two groups, fraudsters selling fake vaccines with serious health risks and public officials seeking to profit from the situation by re-selling legitimate vaccines for between USD 300 and USD 600.


Important Notice
While the information in this article has been prepared in good faith, no representation, warranty, assurance or undertaking (express or implied) is or will be made, and no responsibility or liability is or will be accepted by Deheza Limited or by its officers, employees or agents in relation to the adequacy, accuracy, completeness or reasonableness of this article, or of any other information (whether written or oral), notice or document supplied or otherwise made available in connection with this article. All and any such responsibility and liability is expressly disclaimed.
This article has been delivered to interested parties for information only. Deheza Limited gives no undertaking to provide the recipient with access to any additional information or to update this article or any additional information, or to correct any inaccuracies in it which may become apparent.

Most recent in Health

Cellular level 

Brazil’s cell and gene therapy industry. 

Battling the Buzz

Dengue wars in Latin America.

Galloping Ahead

Argentina’s cloning industry breaks new ground.

Revolutionising pharmaceutical services 

Challenges and opportunities in the Americas. 

LatAm’s fight for a healthier tomorrow

The region's efforts to defeat Hepatitis.

Diabetes spikes

A public health crisis is emerging as diabetes runs rampant across Latin America.

Sleep on it

A recent study claims 3 in 4 Argentinians suffer from some form of sleep disturbance.

Health collapse

Chile’s private health insurance companies face bankruptcy at the hands of government legislation.

Cholera outbreak

PAHO delivers over a million cholera vaccine doses to Haiti as outbreak gathers pace.

Birth dearth

Latin America’s fertility rate continues to fall but what does this mean for the region?